Literature DB >> 25444314

Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study.

Jesús Villar-del-Moral1, Antonio Jiménez-García2, Pilar Salvador-Egea3, Juan M Martos-Martínez4, José M Nuño-Vázquez-Garza5, Mario Serradilla-Martín6, Angel Gómez-Palacios7, Pablo Moreno-Llorente8, Joaquín Ortega-Serrano9, Aitor de la Quintana-Basarrate10.   

Abstract

BACKGROUND: Parathyroid carcinoma (PC) is an uncommon disease that generally is detected postoperatively and traditionally is associated with a poor prognosis. Our purpose was to evaluate treatment outcomes, prognostic factors, and usefulness of some proposed staging systems for this disease.
METHODS: A multicenter review of patients with surgically resected PC was performed, led by the Spanish Association of Surgery. All surgical units affiliated with its endocrine surgery section were invited to answer a questionnaire that collected several hospital-related, clinical, biochemical, operative, pathologic, and follow-up data. Their relationships with prognosis were assessed by both univariate and multivariate analysis, as well as the effectiveness of three staging systems for parathyroid carcinoma. RESULT: Of the 6,863 patients undergoing parathyroidectomy, 62 (0.9%) had PC. Of them, 12 (19.3%) died, in 5 cases (8%) because of disease, and 14 (22.6%) suffered recurrence, after a median follow-up of 55 months. The most predictive independent variables on tumor recurrence were intraoperative tumor rupture (hazard ratio [HR] 6.22; 95% confidence interval [CI] 1.19-32.36; P = .030); the presence of mitotic figures within tumor parenchyma cells (HR 4.76; 95% CI 1.24-18.21; P = .022); and allocation in class III according to Schulte differentiated staging classification (HR 5.23; 95% CI 1.41-19.31; P = .013). As to disease-specific survival, poor outcomes were associated with intraoperative tumor rupture (HR 58.71; 95% CI 2.39-1,439.96; P = .013) and distant recurrence (HR 38.74; 95% CI 3.44-435.62; P = .003).
CONCLUSION: In addition to factors associated with tumor histopathology and stage, prognosis of PC is greatly influenced by surgeon's performance, which emphasizes the importance of preoperative diagnosis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25444314     DOI: 10.1016/j.surg.2014.05.014

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

1.  Tumor Size and Presence of Metastatic Disease at Diagnosis are Associated with Disease-Specific Survival in Parathyroid Carcinoma.

Authors:  Winifred M Lo; Meghan L Good; Naris Nilubol; Nancy D Perrier; Dhaval T Patel
Journal:  Ann Surg Oncol       Date:  2018-07-03       Impact factor: 5.344

2.  Brown Tumors Due to Primary Hyperparathyroidism in a Patient with Parathyroid Carcinoma Mimicking Skeletal Metastases on (18)F-FDG PET/CT.

Authors:  Kim Francis Andersen; Elisabeth Albrecht-Beste
Journal:  Diagnostics (Basel)       Date:  2015-07-09

3.  Somatostatin receptor expression in parathyroid neoplasms.

Authors:  Sara Storvall; Helena Leijon; Eeva Ryhänen; Johanna Louhimo; Caj Haglund; Camilla Schalin-Jäntti; Johanna Arola
Journal:  Endocr Connect       Date:  2019-08       Impact factor: 3.335

4.  MGMT Promoter Methylation and Parathyroid Carcinoma.

Authors:  Sara Storvall; Eeva Ryhänen; Ilkka Heiskanen; Tiina Vesterinen; Frank V Bensch; Jukka Schildt; Soili Kytölä; Auli Karhu; Johanna Arola; Camilla Schalin-Jäntti
Journal:  J Endocr Soc       Date:  2019-07-23

5.  Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience.

Authors:  Loredana De Pasquale; Antonio Mario Bulfamante; Giovanni Felisati; Luca Castellani; Giorgio Ghilardi; Alberto Maria Saibene
Journal:  Int J Endocrinol       Date:  2021-10-07       Impact factor: 3.257

6.  Non-Linear Correlation Between Tumor Size and Survival Outcomes for Parathyroid Carcinoma: A SEER Population-Based Cohort Study.

Authors:  Kun Zhang; Anping Su; Xiaofei Wang; Wanjun Zhao; Linye He; Tao Wei; Zhihui Li; Jingqiang Zhu; Ya-Wen Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-01       Impact factor: 6.055

7.  Distinguishing Parathyromatosis, Atypical Parathyroid Adenomas, and Parathyroid Carcinomas Utilizing Histologic and Clinical Features.

Authors:  Jefree J Schulte; Garrison Pease; Jerome B Taxy; Curtis Hall; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2021-01-04

8.  Clinical characteristics and treatment outcomes of parathyroid carcinoma: A retrospective review of 234 cases.

Authors:  Peisong Wang; Shuai Xue; Shuo Wang; Zhi Lv; Xianying Meng; Guimin Wang; Wei Meng; Jia Liu; Guang Chen
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

9.  Serum circulating miRNA-342-3p as a potential diagnostic biomarker in parathyroid carcinomas: A pilot study.

Authors:  Julia Krupinova; Natalya Mokrysheva; Vasiliy Petrov; Ekaterina Pigarova; Anna Eremkina; Ekaterina Dobreva; Alina Ajnetdinova; Galina Melnichenko; Anatoly Tiulpakov
Journal:  Endocrinol Diabetes Metab       Date:  2021-07-29

10.  Parathyroid Carcinoma: Incidence, Survival Analysis, and Management: A Study from the SEER Database and Insights into Future Therapeutic Perspectives.

Authors:  Asad Ullah; Jaffar Khan; Abdul Waheed; Nitasha Sharma; Elizabeth K Pryor; Tanner R Stumpe; Luis Velasquez Zarate; Frederick D Cason; Suresh Kumar; Subhasis Misra; Sravan Kavuri; Hector Mesa; Nitin Roper; Shahin Foroutan; Nabin Raj Karki; Jaydira Del Rivero; William F Simonds; Nagla Abdel Karim
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.